Top

International Journal of Clinical Oncology

Published in:

01-12-2018 | Original Article

Analysis and treatment of 45 platinum-allergic gynecologic malignant tumors

Authors: Xiaolin Ma, Xiuqin Li

Published in: International Journal of Clinical Oncology | Issue 6/2018

Abstract

Background

This study aimed to explore the potential risk factors of platinum allergy and follow-up treatment to provide a reference for the clinical prevention and treatment of platinum allergic reactions in patients with gynecological tumors.

Methods

The study retrospectively analyzed 45 cases of platinum allergic reactions that occurred in Shengjing Hospital affiliated to China Medical University from August 2010 to July 2016. Analysis of risk factors included the cumulative dose, treatment course and time intervals.

Results

The cumulative carboplatin dose in allergic patients ranged from 900 to 10250 mg (average 4845 mg). The 45 allergic reactions occurred between the 3rd and 25th course of treatment (average 11.4 courses). The average re-treatment interval of carboplatin-allergic patients was 28.1 months, including 93.3% of patients with platinum re-treatment interval of more than 1 year. The allergic reaction occurred in the 2nd or 3rd course of re-treatment in 26 patients, accounting for 70.3% of all patients with recurrence. Seventeen patients were subjected to desensitization therapy, among which 13 cases were well tolerated.

Conclusions

Patients who received more than 8 courses of carboplatin or a cumulative dose of more than 3500 mg were the high-risk population for platinum allergy. The 2nd and 3rd treatment course after restarting carboplatin treatment after an interval time of more than 1 year was the high incident period of carboplatin allergy. Skin tests should be conducted in patients with high risk of carboplatin allergy. In cases of carboplatin allergy, patients could receive carboplatin or oxaliplatin desensitization therapy.

Morgan JS, Adams M, Mason MD (1994) Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma. Eur J Cancer 30A(8):1205–1206CrossRef

Markman M, Kennedy A, Webster K et al (1999) Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 17(4):1141–1145CrossRef

Hendrick AM, Simmons D, Cantwell BM (1992) Allergic reactions to carboplatin. Ann Oncol 3(3):239–240CrossRef

Koren C, Yerushalmi R, Katz A et al (2002) Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy. Am J Clin Oncol 25(6):625–626CrossRef

Bautista MA, Stevens WT, Chen CS et al (2010) Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature. J Hematol Oncol 3:12. https://doi.org/10.1186/1756-8722-3-12 CrossRefPubMedPubMedCentral

Shibata Y, Ariyama H, Baba E et al (2009) Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan. Int J Clin Oncol 14(5):397–401CrossRef

Mariana C, Nichole M, David E et al (2008) Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 122(3):574–580CrossRef

Williams CJ, Whitehouse JM (1979) Cis-platinum: a new anticancer agent. Br Med J 1(6179):1689–1691CrossRef

Keys HM, Bundy BN, Stehman FB et al (1999) Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340(15):1154–1161CrossRef

10.

Morris M, Eifel PJ, Lu J et al (1999) Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340(15):1137–1143CrossRef

11.

Peters WA, Liu PY, Barrett RJ et al (2000) Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18(8):1606–1613CrossRef

12.

Whitney CW, Sause W, Bundy BN et al (1999) Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 17(5):1339–1348CrossRef

13.

Rose PG, Bundy BN, Watkins EB et al (1999) Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340(15):1144–1153CrossRef

14.

Alberts DS, Canetta R, Mason-Liddil N (1990) Carboplatin in the first-line chemotherapy of ovarian cancer. Semin Oncol 17(1 Suppl 2):S54–S60

15.

Viswanathan AN, Moughan J, Miller BE et al (2015) NRG Oncology/RTOG 0921: a phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. Cancer 121(13):2156–2163CrossRef

16.

Yang L, Guo J, Shen Y et al (2015) Clinical efficacy and safety of paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for stage IB2-IIB cervical cancer. Int J Clin Exp Med 8(8):13690–13698PubMedPubMedCentral

17.

Symonds RP, Gourley C, Davidson S et al (2015) Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol 16(15):1515–1524CrossRef

18.

Souglakos J, Syrigos K, Potamianou A et al (2004) Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial. Ann Oncol 15(8):1204–1209CrossRef

19.

Giacchetti S, Perpoint B, Zidani R et al (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil–leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18(1):136–147CrossRef

20.

Lee KH, Kim MK, Kim YH et al (2009) Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study. Cancer Chemother Pharmacol 64(2):317–325CrossRef

21.

Chollet P, Bensmaïne MA, Brienza S et al (1996) Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 7(10):1065–1070CrossRef

22.

Bogliolo S, Cassani C, Gardella B et al (2015) Oxaliplatin for the treatment of ovarian cancer. Expert Opin Investig Drugs 24(9):1275–1286CrossRef

23.

Zhang G, Li XP, Liu BJ et al (2013) Oxaliplatin-based combination chemotherapy is still effective for the treatment of recurrent and platinum-resistant epithelial ovarian cancer: results from a single center. Chin Med J (Engl) 126(23):4477–4482

24.

Vici P, Sergi D, Pizzuti L et al (2013) Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients. J Exp Clin Cancer Res 32(1):49. https://doi.org/10.1186/1756-9966-32-49 CrossRefPubMedPubMedCentral

25.

Markman M, Zanotti K, Kulp B et al (2003) Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity. Gynecol Oncol 89(3):514–516CrossRef

26.

Koshiba H, Hosokawa K, Kudo A et al (2009) Incidence of carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies. Int J Gynecol Cancer 19(3):460–465CrossRef

27.

Wang HB, Shen K, Yang JX et al (2009) [Clinical analysis of thirteen cases of hypersensitivity reactions to carboplatin]. Zhonghua Fu Chan Ke Za Zhi 44(11):837–840 (Chinese) PubMed

28.

Schwartz JR, Bandera C, Bradley A et al (2007) Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants’ Hospital. Gynecol Oncol 105(1):81–83CrossRef

29.

Gadducci A, Tana R, Teti G et al (2008) Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Int J Gynecol Cancer 18(4):615–620CrossRef

30.

Lee CW, Matulonis UA, Castells MC (2004) Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol 95(2):370–376CrossRef

31.

Confino-Cohen R, Fishman A, Altaras M et al (2005) Successful carboplatin desensitization in patients with proven carboplatin allergy. Cancer 104(3):640–643CrossRef

32.

Choi J, Harnett P, Fulcher DA (2004) Carboplatin desensitization. Ann Allergy Asthma Immunol 93(2):137–141CrossRef

33.

Rose PG, Metz C, Link N (2014) Desensitization with oxaliplatin in patients intolerant of carboplatin desensitization. Int J Gynecol Cancer 24(9):1603–1606CrossRef

34.

Kolomeyevskaya NV, Lele SB, Miller A et al (2015) Oxaliplatin is a safe alternative option for patients with recurrent gynecologic cancers after hypersensitivity reaction to Carboplatin. Int J Gynecol Cancer 25(1):42–48CrossRef

35.

Caiado J, Venemalm L, Pereira-Santos MC et al (2013) Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy. J Allergy Clin Immunol Pract 1(5):494–500CrossRef

36.

Gomez R, Harter P, Lück HJ et al (2009) Carboplatin hypersensitivity: dose introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study. Int J Gynecol Cancer 19(7):1284–1287CrossRef

37.

Hesterberg PE, Banerji A, Oren E et al (2009) Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol 123(6):1262–1267.e1CrossRef

38.

Iwamoto T, Yuta A, Tabata T et al (2012) Evaluation of basophil CD203c as a predictor of carboplatin-related hypersensitivity reaction in patients with gynecologic cancer. Biol Pharm Bull 35(9):1487–1495CrossRef

Title: Analysis and treatment of 45 platinum-allergic gynecologic malignant tumors
Authors: Xiaolin Ma
Xiuqin Li
Publication date: 01-12-2018
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 6/2018
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-018-1326-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2018

Prognostic and predictive value of plasma d-dimer levels in patients with small-cell lung cancer

A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101)

Novel graded prognostic assessment for colorectal cancer patients with brain metastases

Effect of everolimus treatment for regrown renal angiomyolipoma associated with tuberous sclerosis complex after transcatheter arterial embolization

Prognostic outcome and complications of sentinel lymph node navigation surgery for early-stage cervical cancer

Colorectal obstruction is a potential prognostic factor for stage II colorectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer